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Abstract (words 250) 
Observations in autopsied brain tissue indicate that overactivation of the classical renin-
angiotensin system (cRAS) and underactivity within regulatory RAS pathways (rRAS) are 
associated with pathology in Alzheimer’s disease (AD). The primary aim of this study was to 
investigate whether cerebrospinal fluid (CSF) markers of RAS are altered in AD in relation to 
established CSF markers of disease pathology (lower Aβ42 and elevated tau) and CSF 
markers of capillary dysfunction.  We studied 40 controls and 40 AD cases grouped 
according to a biomarker profile (i.e. AD cases t-tau >400 pg/mL, pTau >60 pg/mL and Aβ42 
<550 pg/mL). ACE1 and ACE2 enzyme activity was measured using fluorogenic peptide 
substrates; sPDGFRβ and albumin level by sandwich ELISA and Angiotensin-I, -II, and 1-7 by 
direct ELISA. CSF Aβ42, total and phosphorylated tau level was previously measured by 
INNOTEST sandwich ELISA. CSF ACE1 activity was significantly elevated in AD (p = 0.008) and 
positively correlated with ACE2 in AD (r = 0.420, p = 0.007).  CSF ACE1 weakly correlated 
with t-tau (r = 0.294, p = 0.066) and p-tau (r = 0.329, p = 0.038) but not with Aβ42 in the 
controls but not in AD. ACE1 correlated positively with sPDGFRβ (r = 0.426, p = 0.007), a 
marker of pericyte injury, and ACE2 correlated positively with albumin (r = 0.422, p = 0.008), 
a marker of blood-brain barrier integrity. CSF angiotensin -I, -II and –(1-7) level was 
unchanged in AD. This cross-sectional CSF study indicates RAS dysfunction in relation to 
capillary damage in AD.  
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Alzheimer’s disease (AD) is characterised neuropathologically by the deposition of 
extracellular Aβ within senile plaques and the accumulation of intracellular tau within 
neurofibrillary tangles [1]. Recent imaging, CSF biomarker studies and disease modelling 
indicate that cerebrovascular dysfunction, including reduced cerebral blood flow, 
neurovascular uncoupling and blood-brain barrier (BBB) breakdown, are major contributors 
to cognitive decline and disease pathology in the early stages of Alzheimer’s disease (AD) [2-
4]. A recent study reported that BBB leakiness and a marker of pericyte injury, indicated by 
increased CSF levels of soluble platelet-derived growth factor receptor β (sPDGFRβ), are 
sensitive markers of cognitive decline in the very early stages of AD independently of CSF Aβ 
and tau [5]. Together, these data support a growing hypothesis that cerebrovascular 
dysfunction is a major and underestimated contributor to cognitive decline and disease 
pathology particularly in the early stages of AD [6]. 
The renin-angiotensin-system (RAS) is a hormonal system that regulates systemic 
blood pressure. The RAS is expressed and functions independently within the brain and is 
dysfunctional in Alzheimer’s disease (AD) (reviewed in [7, 8]). Studies in human post-
mortem brain tissue indicate that overactivation of the classical RAS (cRAS) pathway is 
associated with elevated Aβ and tau pathology in AD [9-12]. Angiotensin-converting 
enzyme-1 (ACE1) activity, the level of angiotensin-II (Ang-II), and the expression of 
angiotensin-II type 1 receptor (AT1R) are all increased in AD [9, 11-13]. Cerebroventricular 
infusion of Ang-II, the main effector peptide of the RAS, accelerates Aβ production (via 
proteolytic cleavage of APP) and promotes the accumulation of disease-modified tau in 




RAS pathways exist within the brain that counteract the classical RAS axis [16-18].  We 
recently reported that ACE2 activity, which is primarily responsible for converting Ang-II to 
Ang(1-7) [19, 20], was reduced by almost 50% in the mid-frontal cortex in AD and was 
related to elevated parenchymal Aβ and tau load [10] and inversely related to elevated 
ACE1 activity.   
Classical RAS-targeting agents, such as ACE1 inhibitors (ACE-Is) and angiotensin-II 
type 1 receptor (At1R) blockers (ARBs) have been shown to reduce the incidence [21-24], 
delay cognitive decline [25] and improve cognition in AD [26]. The protective effects of RAS-
blockers in AD are associated with lower CSF-tau [27] and elevated CSF-Aβ (indicative of 
reduced parenchymal Aβ deposition) [28] and reduced Aβ and tau pathology [29, 30]. 
Together, these data highlight an imbalance in brain RAS in AD comprising classical RAS 
overactivation that is related to disease pathology that is, in part, associated with reduced 
regulatory RAS activity.  
ACE1 and ACE2 are central effectors of the cRAS and rRAS pathways and are 
responsible for the production and catabolism of Ang-II respectively. ACE1 and ACE2 are 
single-span membrane-bound ectoenzymes [31] that are predominantly expressed in 
endothelial and smooth muscle cells throughout the body  but are also localised within 
neuronal cells [32, 33] and non-neuronal glial cells within the CNS [34, 35].  Shedding and 
solubilisation of ACE1 [36] and ACE2 [37] results in the release of the active enzyme in 
various biological fluids including serum and CSF. ACE1 has previously been measured in CSF 
in AD but previous studies have provided inconsistent findings with some studies reporting 




no change [43]. In contrast, ACE2 activity in CSF remains relatively uncharacterised with only 
a single study to-date showing unaltered CSF ACE2 in AD [41].  
The major aim of this study was to investigate if CSF ACE1 and ACE2 activity are 
altered in AD, and if so, whether RAS CSF changes were associated with established CSF 
markers of disease pathology (i.e increased t-tau and p-tau and reduced Aβ42) and novel 





We studied CSF from 40 control and 40 AD cases that were approximately matched 
for age (69.1 y ± 12.1 in controls and 76.3 y ± 6.1 in AD) and distribution of sex across 
cohorts (23M:15F in controls and 25:15F in AD) (Table 1). Measurements of CSF-Aβ42, t-tau 
and p-tau using commercially available sandwich enzyme-linked immunosorbent assays 
(ELISAs) (INNOTEST, Fujirebio, Ghent, Belgium) had previously been determined. All AD 
patients had abnormal CSF levels of the core AD biomarkers (t-tau >400 ng/L, p-tau >60 ng/L 
and Aβ42 <550 ng/L), while controls had normal levels.  The cut-off values used in this study 
are in-line with current clinical practice and closely resemble those outlined by Hansson et 
al. [44]. The present assays were performed on de-identified left-over aliquots from clinical 
diagnostic CSF samples and complied with the Swedish Biobank law (Biobanks in Medical 
Care Act). All procedures were previously approved by the Ethical Committee at the 




histories, including potential use of RAS-targeting or other classes of anti-hypertensives, 
were not collected for participants.  
CSF ACE1 fluorogenic activity assay 
ACE1 activity was measured in CSF using an ACE1 specific FRET peptide substrate 
(Abz-FRK(Dnp)-P) (Biomol International, Exeter, UK) as previously described [10, 11, 13, 45]. 
Recombinant ACE1 (1000-31.1 ng/ml) or CSF (5μl CSF diluted in 45ul assay buffer) was 
incubated with ACE1 substrate (10 μM diluted in assay buffer) for 2.5 h at 26°C. 
Fluorescence was measured with excitation at 320nm and emission at 405nm in a plate 
reader (FLUOstar, BMG Labtech, Aylesbury, UK). All cases were run in duplicate in the 
presence and absence of captopril for 10 minutes at 26°C prior to the addition of the FRET 
substrate – we previously showed that pre-incubation with captopril blocked ACE1 activity 
by over 90% [11, 13]. ACE1 activity was determined by subtracting the fluorescence in the 
captopril-inhibited from the untreated wells. A serial dilution of recombinant human ACE1 
and measurements on carry-over samples across all plates was used to minimise variation 
between plates. ACE1 activity was expressed as relative fluorescence units (r.f.u). 
CSF ACE2 fluorogenic activity assay 
ACE2 activity was measured using the ACE2 specific FRET substrate (Mca-APK(Dnp) 
(Enzo Life Sciences, Exeter, UK) as previously described [10]. Recombinant ACE2 (440 – 6 
ng/ml) (R&D systems, Cambridge, UK) or CSF (50 μl undiluted) was incubated with the FRET 
substrate (10 μM) diluted in assay buffer (75 mM Tris, 1M NaCl, pH7.5) for 3 h at 37 C. 
Recombinant ACE2 and CSF samples were assayed in duplicate in the presence or absence 




water for 10 mins at 37°C prior to the addition of the fluorogenic substrate. ACE2 activity 
was determined by subtracting the fluorescence in the inhibited from the untreated wells. 
Cleavage of the ACE2 FRET peptide was measured using a microplate reader (BMG Labtech, 
Aylesbury, UK) at excitation/emission wavelength 330/390nm. A serial dilution of 
recombinant human ACE2 and measurements on carry-over samples across all plates was 
used to minimise variation between plates. ACE2 activity was expressed in relative 
fluorescence units (r.f.u). 
CSF Angiotensin-I, -II and -(1-7) measurement by direct ELISA 
Ang-I, -II and Ang-(1-7) concentrations were measured by direct ELISA as previously 
described  [9, 10].  Serial dilutions of recombinant human Ang-I, Ang-II and Ang-(1-7) (5000-
78.125 pg/ml) (Abcam, Cambridge, UK) or CSF samples (100ul undiluted) were incubated for 
2 hours in clear high-binding capacity NUNC maxisorp plates (ThermoFisher Scientific, 
Waltham, MA, USA) at 26°C with shaking. The wells were washed five-times in PBS with 
0.05% tween-20 and blocked for 1 hour in 1 % PBS: BSA (Sigma Aldrich, Dorset, UK). After 
another five washes, the wells were incubated with either biotinylated anti-human Ang-I 
(diluted 1 in 100 in PBS), biotinylated anti-human Ang-II (diluted 1 in 500 in PBS), or 
biotinylated anti-human Ang-(1-7) (diluted 1 in 100 in PBS) (all from Cloud-Clone, Wuhan, 
China),  for 2 hours at 26°C with shaking, followed by a further wash step. Plates were 
incubated with streptavadin:HRP (1:200) in PBS:0.01% Tween-20 for 20 minutes at room 
temperature in the dark and TMB substrate (R&D systems) was added after a further wash 
and left to develop in the dark for 20 minutes. The reaction was stopped following the 
addition of 2N sulphuric acid and the absorbance was read at 450nm using a FLUOstar 




interpolated for each sample measured in duplicate following interpolation from respective 
standard curves generated by serially diluting recombinant standards. We previously 
demonstrated specificity of each assay which showed specificity for the respective target 
with minimal cross reactivity with other closely-related angiotensin peptides [9, 10]. 
ELISA measurement of CSF sPDGFRβ  
CSF soluble PDGFRβ (sPDGFRβ) level was measured using a commercially available 
sandwich ELISA (Invitrogen Cat no EHPDGFRB) (ThermoFisher Scientific, Loughborough, UK) 
following the manufacturer’s protocol. CSF samples (100μl) were loaded without dilution. 
Standards, samples and blanks were added in duplicate. Absorbance was read at 450 nM 
following the addition of 2N sulfuric acid in a FLUOstar OPTIMA plate reader (BMG labtech, 
Aylesbury, UK). sPDGFRβ concentration in samples was interpolated from the standard 
curve for each case, derived from the serial dilution of recombinant PDGFRβ (18000-24 
pg/ml). The average of duplicate measurements for each sample is presented. 
ELISA measurement of CSF albumin 
CSF albumin level was measured using a commercially available sandwich ELISA (Cat 
no 108788) (Abcam, Cambridge, UK) following the manufacturer’s protocol. CSF samples 
were diluted 1 in 2000 in proprietary dilution buffer supplied with the kit. Standards, 
samples and blanks were added in duplicate. Absorbance was read at 450nM in a FLUOstar 
OPTIMA plate reader (BMG labtech, Aylesbury, UK). Albumin concentration in each sample 
was interpolated from the standard curve for each case, derived from the serial dilution of 





Unpaired two-tailed t-tests or ANOVA with Bonferroni post-hoc analysis was used for 
comparisons between groups, and Pearson's test was used to assess linear correlation with 
the help of SPSS version 24 (SPSS, Chicago) and GraphPad Prism version 6 (GraphPad 
Software, La Jolla, CA). P-values < 0.05 were considered statistically significant. 
 
Results 
ACE1 enzyme activity is elevated in CSF from Alzheimer’s disease patients and correlates 
positively with ACE2 activity 
CSF ACE1 activity was significantly higher in AD (2148 rfu ± 153.8) compared to 
controls (1635 rfu ± 110.9) (p = 0.008) (Figure 1A). CSF ACE2 activity was unchanged in AD 
(360.1 rfu ± 24.8) compared to controls (318.1 rfu ± 16.3) (p = 0.169) (Figure 1B). We 
previously reported an inverse relationship between ACE1 and ACE2 in the mid-frontal 
cortex in AD [10]. We examined the relationship between ACE1 and ACE2 in CSF and found a 
positive correlation in AD (r = 0.420, p = 0.007) but not in controls (r = 0.190, p = 0.239) 
(Figure 1C).  
CSF ACE1 activity did not vary according to age in either controls (r = 0.056, p = 
0.732) or AD (r = 0.114, p = 0.489) (Figure 2A) however, CSF ACE2 activity correlated 
positively with age in controls (r = 0.423, p = 0.0065) but not in AD (p = 0.172, p = 0.290) 





CSF ACE1 and ACE2 enzyme activity are not strongly associated with established CSF markers 
of disease pathology in AD 
We previously reported that increased ACE1 and reduced ACE2 activity are 
associated with parenchymal Aβ and tau load in mid-frontal cortex in AD [10, 11, 13]. . We 
examined the relationship between CSF ACE1 and ACE2 activity with established CSF 
markers of disease pathology (t-tau, p-tau and Aβ42). CSF ACE1 activity did not correlate 
with CSF t-tau in either control (r = 0.294, p = 0.066) or AD group (r = -0.01, p = 0.945) 
(Figure 3A) but was weakly positively correlated with CSF p-tau in controls (r = 0.329, p = 
0.038) but not AD (r = 0.135, p = 0.413) (Figure 3B). CSF ACE1 did not correlate with Aβ42 in 
either control (r = 0.216, p = 0.179) or AD groups (r = -0.05, p = 0.761) (Figure 3C). CSF ACE2 
did not correlate with CSF-p-tau, CSF-t-tau or CSF-Aβ42 in either the AD or control groups 
(Table 2) 
 
CSF ACE1 and ACE2 activity correlates with markers of capillary damage  
ACE1 is enriched in cerebral vessels [46] and there is evidence of vascular breakdown in AD 
[47] that together are suggestive of a link between RAS activation and vascular dysfunction 
in AD. Here we examined the relationship between CSF ACE1 and ACE2 with albumin, an 
established CSF marker of BBB leakiness, and with soluble PDGFRβ, a marker of pericyte 
injury that is elevated in AD [5]. A positive correlation was observed between CSF ACE1 
enzyme activity and CSF sPDGFRβ level in AD cases alone (r = 0.426, p = 0.007) but not in 
controls (r = 0.112, p = 0.482) (Figure 4A). CSF ACE2 in contrast did not correlate with CSF 
sPDGRβ in either control (r = 0.047, p = 0.778) or AD (r = 0.121, p = 0.483) (Figure 4B) but did 




0.179; p = 0.282) (Figure 4D). CSF ACE1 activity did not correlate with CSF albumin in either 
controls (p = 0.038, p = 0.820) or AD (r = 0.129; p = 0.439) (Figure 4C).  
 
CSF angiotensin -I, -II, and –(1-7) level was unaltered in AD 
Angiotensin-I, II and (1-7) levels were unchanged between AD and controls in CSF 
(Figure 5) and did not correlate with Aβ, t-tau and p-tau level (data not shown). 
 
Discussion 
In this study, we explored disease-related changes in CSF markers of RAS in relation 
to established CSF markers of disease pathology (lower Aβ42 and elevated t-tau and p-tau) 
and markers of capillary damage (sPDGFRβ and albumin) in clinical diagnostic CSF samples in 
AD. Our observational study indicates that CSF ACE1 activity is elevated in AD. CSF ACE1 was 
positively correlated with CSF ACE2 in AD. We also observed that CSF ACE2 activity was 
positively associated with age in the control cohort suggesting it is elevated as a result of 
normal ageing. In contrast to our recent findings in human autopsy brain tissue, there was 
little evidence of a relationship between CSF ACE1 and ACE2 with CSF t-tau,p-tau or Aβ42. 
We did, however, find moderately strong associations between CSF ACE1 activity and 
sPDGFRβ, a marker of pericyte damage, and between CSF ACE2 activity and CSF albumin 
level, a marker of BBB leakiness, within the AD cohort only. Angiotensin peptide 
concentrations were expressed at low levels in CSF and were unaltered in AD. These novel 




capillary dysfunction in AD. Together, this study provides further mechanistic insights and 
improves our current understanding of the role of RAS in AD.  
An imbalance in RAS resulting in overactivation of the classical RAS (disease-
associated) pathway and reduced activity in regulatory RAS, is observed in human brain 
tissue in association with disease pathology in AD [9-11, 13]. In this study, CSF ACE1 activity 
was increased in AD supporting findings from previous studies in post-mortem tissue [11, 
13] and the majority of CSF studies [38, 39]. CSF ACE2 activity was unchanged in AD 
supporting a recent study [41], but it should be noted that CSF ACE2 activity was higher in 
AD albeit non-significantly in this study possibly due to the relatively small cohort size. 
Interestingly, ACE2 was increased in association with ageing in the controls but not in AD, 
potentially indicating that ACE2 changes precede changes associated with disease 
pathology. CSF ACE1 activity correlated positively with CSF ACE2 activity in CSF whereas we 
previously reported the opposite in brain tissue i.e. elevated ACE1 and reduced ACE2 [10]. 
ACE1 and ACE2 are predominantly membrane bound but both can be cleaved at their 
respective transmembrane domains and are released extracellularly (solubilised) in an 
active form [48, 49]. Shedding of membrane-bound ACE2 by ADAM-17, resulting in loss of 
membrane-bound ACE2 has previously been implicated in the pathogenesis of neurogenic 
hypertension [50] and could also account for the differences between brain activity and CSF 
activity in AD. ACE1 in contrast is elevated in both brain tissue and CSF, it is currently 
unclear whether over-production of ACE2 or post-translational modifications are 
responsible for elevated ACE1 in AD.  
We previously reported that ACE1 correlated positively with Aβ in AD, and reduced 




association between CSF ACE1 and the ratio of p-tau181:Aβ42 has previously been reported in 
two separate cohorts: the Knight Alzheimer’s Disease Research Center (N = 311) and the 
Alzheimer’s Disease Neuroimaging Initiative (N = 293) [51]. In contrast, we did not find 
strong evidence to support similar changes between CSF RAS and markers of disease 
pathology in CSF. This could be due to many factors and potential limitations in the current 
study including the small cohort size and/or the fact the groups were based on CSF 
biomarkers levels, rather than clinical or pathological diagnosis. We also have no 
information on hypertension status or use of RAS-targeting anti-hypertensives that may 
conceal a potential relationship. It is also unclear and difficult to interpret why we observed 
a positive correlation between CSF ACE1 and p-tau in controls but not AD. It should, 
however, also be noted that changes in CSF reflect global changes throughout the brain and 
do not necessarily reflect specific regional changes previously reported within the brain. This 
is also an observational cross-sectional study and does not provide any clues as to the 
temporal sequence of RAS activation in relation to disease pathology. Further studies are 
required to address these current limitations and confirm or refute our current findings. 
In contrast, we have found stronger evidence of a relationship between RAS 
overactivation and capillary breakdown indicated by moderate associations between CSF 
ACE1 and ACE2 enzyme activities with CSF markers of capillary damage in AD, namely 
pericyte damage (elevated CSF sPDGFRβ) and BBB breakdown (elevated CSF albumin) 
respectively. The microvasculature has been shown to degenerate in AD [47] and ACE1 
activity is highly enriched in brain microvessels [46] that together are suggestive of a 
possible involvement of RAS in vascular disruption in AD.  Recent studies also indicate that 
vascular dysfunction, including BBB breakdown and pericyte loss, are major contributors to 




marker of pericyte injury (although PDGFRβ is also expressed by sub-populations of reactive 
glia), has recently been reported in CSF and is associated with BBB leakiness in the ageing 
and diseased hippocampus [29], and has been shown to be a significant predictor of 
cognitive decline independently of Aβ and tau in the early stages of disease [5]. Our data 
indicate a relationship between RAS activation and both pericyte loss and BBB function. This 
potential link is supported by indirect evidence of a relationship between RAS and BBB 
permeability in vitro [53] and in vivo [54]. Ang-II is a potent vasoconstrictor and mediates 
pericyte contraction and vessel constriction in vessel extracts from rat retina via AT1R 
activation [55]. Pericyte contraction and subsequent vessel constriction may be a major 
contributor to cerebral hypoperfusion in AD [56] and is likely to also lead to pericyte injury 
and release of soluble PDGFRβ. Collectively our findings indicate a potential relationship 
between RAS activation and vascular dysfunction in AD that warrants further investigation.  
Much less is known regarding changes in angiotensin peptides in AD. We recently 
reported that Ang-II and Ang-III, despite short half-lives, were detectable in post mortem 
brain tissue, and were elevated in AD in relation to markers of disease pathology [9]. 
Despite changes in brain tissue, the levels of Ang-I, Ang-II and Ang-(1-7) were unchanged in 
CSF and did not correlate with CSF markers of disease or vascular function. The differences 
between brain tissue and CSF measures may reflect the relative instability and shorter half-
life of angiotensin peptides in CSF compared to brain. Another possibility that cannot be 
addressed in this study is that CSF changes in angiotensin peptide level may first require 
acute or chronic and sustained changes in the activity of brain ACE1 and ACE2. 
This study has several limitations which we have already been mentioned, including 




relating to the de-identified AD cases, including cognitive assessment and disease status 
markers. This is also an observational cross-sectional study and does not provide clues as to 
the timing and regional changes in RAS in relation to disease and vascular markers and it is 
also unclear what percentage of the participants were prescribed RAS-targeting anti-
hypertensives.  Despite these limitations, which will need to be carefully addressed in future 
studies, this study still provides novel insights into the potential relationship between RAS 
activation and capillary damage in AD and provides further evidence of a link between RAS 
and the pathogenesis of AD.  
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Figure 1. ACE1 and ACE2 activity in cerebrospinal fluid (CSF) in Alzheimer’s disease (AD). A-
B Bar charts showing ACE1 and ACE2 enzyme activity in CSF in Alzheimer’s disease (AD) 
compared to age-matched controls. Bars represent the mean level and standard error of the 
mean. ** P < 0.01 C Scatterplot showing relationship between CSF ACE1 and ACE2 grouped 
into AD and controls. The best-fit linear regression lines and 95% confidence intervals are 













Figure 2: Relationship between CSF ACE1 and ACE2 enzyme activity in relation to age and 
sex in CSF in normal ageing and Alzheimer’s disease (AD). A-B Scatterplots showing the 
relationship between ACE1 and ACE2 in normal ageing (blue) and AD (red). ACE1 did not 
correlate with age in either cohort whereas a positive correlation (r = 0.423, p = 0.0065) was 
observed between ACE2 and age in controls only.  Each point in the scatterplot indicates a 
single individual. The best-fit linear regression lines and 95% confidence intervals are 
superimposed. C-D Bar charts show CSF ACE1 and ACE2 activity in control and AD groups 






Figure 3: Relationship between CSF ACE1 and established CSF markers of disease 
pathology in Alzheimer’s disease. A-C Scatterplots showing the relationship between ACE1 
activity and total tau (t-tau), phosphorylated tau (p-tau) and Aβ42 in CSF in AD and age-
matched controls. ACE1 enzyme activity weakly correlated with p-tau (r = 0.329, p = 0.038) 
in controls but not AD but all other correlations were not statistically significant.  Each point 
in the scatterplot indicates a single individual. The best-fit linear regression lines and 95% 













Figure 4. Relationship between CSF ACE1 and ACE2 with CSF markers of vascular 
dysfunction in Alzheimer’s disease. A-D Scatterplots showing relationship between CSF 
ACE1 and ACE2 enzyme activity with markers of pericyte loss (elevated sPDGFRβ) and BBB 
breakdown (elevated albumin) in Alzheimer’s disease (AD). ACE1 positively correlated with 
sPDGFRβ (r = 0.426, p = 0.007) and ACE2 positively correlated with CSF albumin (r = 0.422, p 
= 0.008) in AD. Each point in the scatterplot indicates a single individual. The best-fit linear 





Figure 5. Angiotensin peptides are unchanged in CSF in Alzheimer’s disease. Bar charts 
showing angiotensin-I, -II and –(1-7) level in a subset of CSF samples (20 AD Vs 20 controls) 
























t-tau (ng/L) p-tau  
(ng/L) 
Control 40 69.1 ± 12.1 23:16 825.3 ± 32.4 235.4 ± 11.6 40.6 ± 1.6 
AD 40 76.3  ±  6.1 25:15 431.3 ± 12.2 724.1 ± 35.4 84.6 ± 3.1 
 
Table 2: A relationship between CSF ACE2 activity and markers of disease pathology in CSF 
was not observed in Alzheimer’s disease. 
 
t-tau (ng/L) p-tau (ng/L) Aβ42 (ng/L)  
AD  
alone 
(N = 40) 
r = 0.113 
p = 0.487  
r = 0.076 
P = 0.643 
r = -0.063 
P = 0.700 
Control  
alone 
(N = 40) 
r = 0.245 
p = 0.128  
r = 0.183 
P = 0.259 
r = 0.140 
P = 0.390 
 
